Found: 88
Select item for more details and to access through your institution.
A RANDOMIZED TRIAL OF OBSERVATION VERSUS RADIOTHERAPY IN PRIMARY MEDIASTINAL B‐CELL LYMPHOMA PATIENTS WITH COMPLETE METABOLIC RESPONSE AFTER STANDARD IMMUNOCHEMOTHERAPY.
- Published in:
- Hematological Oncology, 2023, v. 41, p. 48, doi. 10.1002/hon.3163_19
- By:
- Publication type:
- Article
EFFICACY AND SAFETY OF MOLTO, A MULTICENTER, OPEN LABEL, PHASE II CLINICAL TRIAL EVALUATING VENETOCLAX, ATEZOLIZUMAB AND OBINUTUZUMAB COMBINATION IN RICHTER SYNDROME.
- Published in:
- Hematological Oncology, 2023, v. 41, p. 62, doi. 10.1002/hon.3163_27
- By:
- Publication type:
- Article
BASELINE PET RADIOMICS OUTPERFORMS CLINICAL RISK SCORES IN PREDICTING PRIMARY MEDIASTINAL B‐CELL LYMPHOMA OUTCOME: INSIGHTS FROM THE IELSG37 STUDY.
- Published in:
- Hematological Oncology, 2023, v. 41, p. 90, doi. 10.1002/hon.3163_54
- By:
- Publication type:
- Article
RITUXIMAB AND IBRUTINIB COMBINATION IS SAFE AND EFFECTIVE IN UNTREATED SPLENIC AND NODAL MARGINAL ZONE LYMPHOMAS: PLANNED SUBSET ANALYSIS OF THE IELSG47/MALIBU PHASE II STUDY.
- Published in:
- Hematological Oncology, 2023, v. 41, p. 104, doi. 10.1002/hon.3163_65
- By:
- Publication type:
- Article
1998–2023 TWENTY‐FIVE YEARS OF COMMITMENT TO IMPROVING OUR UNDERSTANDING OF LYMPHOMA.
- Published in:
- Hematological Oncology, 2023, v. 41, p. 113, doi. 10.1002/hon.3163_74
- By:
- Publication type:
- Article
IL16 PRODUCTION IS A MECHANISM OF RESISTANCE TO BTK INHIBITORS AND TO R‐CHOP.
- Published in:
- Hematological Oncology, 2023, v. 41, p. 188, doi. 10.1002/hon.3163_118
- By:
- Publication type:
- Article
Primary lymphoma of the female genital tract: a retrospective survey of the International Extranodal Lymphoma Study Group (IELSG35).
- Published in:
- Hematological Oncology, 2023, v. 41, p. 412, doi. 10.1002/hon.3164_303
- By:
- Publication type:
- Article
Equine multisystemic eosinophilic epitheliotropic disease in two horses in Italy.
- Published in:
- Equine Veterinary Education, 2022, v. 34, n. 10, p. e413, doi. 10.1111/eve.13571
- By:
- Publication type:
- Article
Cost-Effectiveness of Shortening Treatment Duration Based on Interim PET Outcome in Patients With Diffuse Large B-cell Lymphoma.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2022, v. 22, n. 6, p. 382, doi. 10.1016/j.clml.2021.11.008
- By:
- Publication type:
- Article
ENDPOINTS IN MARGINAL ZONE LYMPHOMAS: A SYSTEMATIC REVIEW REVEALS WIDE HETEROGENEITY ACROSS TRIALS AND CALLS FOR STANDARDIZATION.
- Published in:
- Hematological Oncology, 2021, v. 39, p. 1, doi. 10.1002/hon.27_2881
- By:
- Publication type:
- Article
DEVELOPMENT AND VALIDATION OF A PET RADIOMICS PROGNOSTIC MODEL FOR DIFFUSE LARGE B CELL LYMPHOMA.
- Published in:
- Hematological Oncology, 2021, v. 39, p. 1, doi. 10.1002/hon.22_2879
- By:
- Publication type:
- Article
INTENSIFIED (INTRAVENOUS AND INTRATHECAL) CNS PROPHYLAXIS IN PRIMARY TESTICULAR DIFFUSE LARGE B‐CELL LYMPHOMA: 5‐YEAR RESULTS OF THE IELSG30 TRIAL.
- Published in:
- Hematological Oncology, 2021, v. 39, p. 1, doi. 10.1002/hon.48_2879
- By:
- Publication type:
- Article
RADIATION FREE THERAPY OR THE INITIAL TREATMENT OF GOOD PROGNOSIS EARLY NON‐BULKY HODGKIN LYMPHOMA, DEFINED BY A LOW METABOLIC TUMOR VOLUME AND A NEGATIVE PET‐2 ‐ RAFTING TRIAL.
- Published in:
- Hematological Oncology, 2021, v. 39, p. 1, doi. 10.1002/hon.158_2880
- By:
- Publication type:
- Article
INTEGRATION OF BASELINE METABOLIC PARAMETERS AND MUTATIONAL PROFILE PREDICTS OUTCOME IN DLBCL PATIENTS. A POST HOC ANALYSIS OF SAKK38/07 STUDY.
- Published in:
- Hematological Oncology, 2021, v. 39, p. 1, doi. 10.1002/hon.18_2879
- By:
- Publication type:
- Article
IMPACT OF DIFFERENT INDUCTION REGIMENS ON THE OUTCOME OF PRIMARY MEDIASTINAL B CELL LYMPHOMA IN THE PROSPECTIVE IELSG 37 TRIAL.
- Published in:
- Hematological Oncology, 2021, v. 39, p. 1, doi. 10.1002/hon.49_2879
- By:
- Publication type:
- Article
SAKK 36/13 ‐ IBRUTINIB PLUS BORTEZOMIB AND IBRUTINIB MAINTENANCE FOR RELAPSED AND REFRACTORY MANTLE CELL LYMPHOMA: FINAL REPORT OF A PHASE I/II TRIAL OF THE EUROPEAN MCL NETWORK.
- Published in:
- Hematological Oncology, 2021, v. 39, p. 1, doi. 10.1002/hon.62_2879
- By:
- Publication type:
- Article
MYC/BCL2/BCL6 triple hit lymphoma of the pericardium: a case report and review of the literature.
- Published in:
- 2020
- By:
- Publication type:
- Letter
INTEGRATION BETWEEN METABOLIC TUMOUR VOLUME AND METABOLIC HETEROGENEITY PREDICTS OUTCOME OF DLBCL LYMPHOMA PATIENTS IN THE SAKK 38/07 STUDY COHORT.
- Published in:
- Hematological Oncology, 2019, v. 37, p. 77, doi. 10.1002/hon.47_2629
- By:
- Publication type:
- Article
INTERNATIONAL PROGNOSTIC SCORE FOR EARLY STAGE CHRONIC LYMPHOCYTIC LEUKEMIA (IPS‐A).
- Published in:
- Hematological Oncology, 2019, v. 37, p. 81, doi. 10.1002/hon.51_2629
- By:
- Publication type:
- Article
PREDICTIVE VALUE OF POD24 VALIDATION IN FOLLICULAR LYMPHOMA PATIENTS INITIALLY TREATED WITH CHEMOTHERAPY‐FREE REGIMENS IN A POOLED ANALYSIS OF THREE RANDOMIZED TRIALS OF THE SWISS GROUP FOR CLINICAL CANCER RESEARCH (SAKK).
- Published in:
- Hematological Oncology, 2019, v. 37, p. 111, doi. 10.1002/hon.73_2629
- By:
- Publication type:
- Article
THE ANTIBODY‐DRUG CONJUGATE (ADC) LONCASTUXIMAB TESIRINE (ADCT‐402) TARGETING CD19 SHOWS STRONG IN VITRO ANTI‐LYMPHOMA ACTIVITY BOTH AS SINGLE AGENTS AND IN COMBINATION.
- Published in:
- Hematological Oncology, 2019, v. 37, p. 129, doi. 10.1002/hon.90_2629
- By:
- Publication type:
- Article
PROGNOSTIC IMPLICATIONS OF THE MICROENVIRONMENT IN FOLLICULAR LYMPHOMA UNDER RITUXIMAB AND RITUXIMAB+LENALIDOMIDE THERAPY. A TRANSLATIONAL STUDY OF THE SAKK35/10 TRIAL.
- Published in:
- Hematological Oncology, 2019, v. 37, p. 149, doi. 10.1002/hon.107_2629
- By:
- Publication type:
- Article
EARLY PROGRESSION OF DISEASE (POD24) PREDICTS SHORTER SURVIVAL IN MALT LYMPHOMA PATIENTS RECEIVING SYSTEMIC TREATMENT.
- Published in:
- Hematological Oncology, 2019, v. 37, p. 179, doi. 10.1002/hon.136_2629
- By:
- Publication type:
- Article
COPANLISIB SYNERGIES WITH CONVENTIONAL AND TARGETED AGENTS INCLUDING VENETOCLAX IN PRECLINICAL MODELS OF B‐ AND T‐CELL LYMPHOMAS.
- Published in:
- Hematological Oncology, 2019, v. 37, p. 318, doi. 10.1002/hon.127_2630
- By:
- Publication type:
- Article
MECHANISMS OF SECONDARY RESISTANCE TO IDELALISIB IN MARGINAL ZONE LYMPHOMA.
- Published in:
- Hematological Oncology, 2019, v. 37, p. 319, doi. 10.1002/hon.128_2630
- By:
- Publication type:
- Article
THE FIRST‐IN‐CLASS ETS INHIBITOR TK‐216 INTERFERES WITH ETS TRANSCRIPTION FACTORS AND SYNERGIZE WITH LENALIDOMIDE IN LYMPHOMA.
- Published in:
- Hematological Oncology, 2019, v. 37, p. 322, doi. 10.1002/hon.132_2630
- By:
- Publication type:
- Article
THE ANTI‐CD25 ANTIBODY‐DRUG CONJUGATE CAMIDANLUMAB TESIRINE (ADCT‐301) PRESENTS A STRONG PRECLINICAL ACTIVITY BOTH AS SINGLE AGENT AND IN COMBINATION IN LYMPHOMA CELL LINES.
- Published in:
- Hematological Oncology, 2019, v. 37, p. 323, doi. 10.1002/hon.134_2630
- By:
- Publication type:
- Article
SIMULTANEOUS BET/CREBBP/EP300 TARGETING APPROACH COMPARED TO SINGLE BET OR CREBBP/EP300 INHIBITION IN DIFFUSE LARGE B‐CELL LYMPHOMA (DLBCL).
- Published in:
- Hematological Oncology, 2019, v. 37, p. 512, doi. 10.1002/hon.196_2631
- By:
- Publication type:
- Article
EG‐011 IS A NOVEL SMALL MOLECULE WITH IN VITRO AND IN VIVO ANTI‐TUMOR ACTIVITY AGAINST LYMPHOMA.
- Published in:
- Hematological Oncology, 2019, v. 37, p. 513, doi. 10.1002/hon.197_2631
- By:
- Publication type:
- Article
A MULTICENTER, OPEN LABEL, UNCONTROLLED, PHASE II TRIAL EVALUATING SAFETY AND EFFICACY OF VENETOCLAX, ATEZOLIZUMAB ANDOBINUTUZUMAB IN RICHTER TRANSFORMATION FROM CLL.
- Published in:
- Hematological Oncology, 2019, v. 37, p. 557, doi. 10.1002/hon.4_2632
- By:
- Publication type:
- Article
INTEGRATION BETWEEN METABOLIC TUMOUR VOLUME AND METABOLIC HETEROGENEITY PREDICTS OUTCOME OF DLBCL LYMPHOMA PATIENTS IN THE SAKK 38/07 STUDY COHORT.
- Published in:
- Hematological Oncology, 2019, v. 37, p. 77, doi. 10.1002/hon.47_2629
- By:
- Publication type:
- Article
INTERNATIONAL PROGNOSTIC SCORE FOR EARLY STAGE CHRONIC LYMPHOCYTIC LEUKEMIA (IPS‐A).
- Published in:
- Hematological Oncology, 2019, v. 37, p. 81, doi. 10.1002/hon.51_2629
- By:
- Publication type:
- Article
PREDICTIVE VALUE OF POD24 VALIDATION IN FOLLICULAR LYMPHOMA PATIENTS INITIALLY TREATED WITH CHEMOTHERAPY‐FREE REGIMENS IN A POOLED ANALYSIS OF THREE RANDOMIZED TRIALS OF THE SWISS GROUP FOR CLINICAL CANCER RESEARCH (SAKK).
- Published in:
- Hematological Oncology, 2019, v. 37, p. 111, doi. 10.1002/hon.73_2629
- By:
- Publication type:
- Article
THE ANTIBODY‐DRUG CONJUGATE (ADC) LONCASTUXIMAB TESIRINE (ADCT‐402) TARGETING CD19 SHOWS STRONG IN VITRO ANTI‐LYMPHOMA ACTIVITY BOTH AS SINGLE AGENTS AND IN COMBINATION.
- Published in:
- Hematological Oncology, 2019, v. 37, p. 129, doi. 10.1002/hon.90_2629
- By:
- Publication type:
- Article
PROGNOSTIC IMPLICATIONS OF THE MICROENVIRONMENT IN FOLLICULAR LYMPHOMA UNDER RITUXIMAB AND RITUXIMAB+LENALIDOMIDE THERAPY. A TRANSLATIONAL STUDY OF THE SAKK35/10 TRIAL.
- Published in:
- Hematological Oncology, 2019, v. 37, p. 149, doi. 10.1002/hon.107_2629
- By:
- Publication type:
- Article
EARLY PROGRESSION OF DISEASE (POD24) PREDICTS SHORTER SURVIVAL IN MALT LYMPHOMA PATIENTS RECEIVING SYSTEMIC TREATMENT.
- Published in:
- Hematological Oncology, 2019, v. 37, p. 179, doi. 10.1002/hon.136_2629
- By:
- Publication type:
- Article
COPANLISIB SYNERGIES WITH CONVENTIONAL AND TARGETED AGENTS INCLUDING VENETOCLAX IN PRECLINICAL MODELS OF B‐ AND T‐CELL LYMPHOMAS.
- Published in:
- Hematological Oncology, 2019, v. 37, p. 318, doi. 10.1002/hon.127_2630
- By:
- Publication type:
- Article
MECHANISMS OF SECONDARY RESISTANCE TO IDELALISIB IN MARGINAL ZONE LYMPHOMA.
- Published in:
- Hematological Oncology, 2019, v. 37, p. 319, doi. 10.1002/hon.128_2630
- By:
- Publication type:
- Article
THE FIRST‐IN‐CLASS ETS INHIBITOR TK‐216 INTERFERES WITH ETS TRANSCRIPTION FACTORS AND SYNERGIZE WITH LENALIDOMIDE IN LYMPHOMA.
- Published in:
- Hematological Oncology, 2019, v. 37, p. 322, doi. 10.1002/hon.132_2630
- By:
- Publication type:
- Article
THE ANTI‐CD25 ANTIBODY‐DRUG CONJUGATE CAMIDANLUMAB TESIRINE (ADCT‐301) PRESENTS A STRONG PRECLINICAL ACTIVITY BOTH AS SINGLE AGENT AND IN COMBINATION IN LYMPHOMA CELL LINES.
- Published in:
- Hematological Oncology, 2019, v. 37, p. 323, doi. 10.1002/hon.134_2630
- By:
- Publication type:
- Article
SIMULTANEOUS BET/CREBBP/EP300 TARGETING APPROACH COMPARED TO SINGLE BET OR CREBBP/EP300 INHIBITION IN DIFFUSE LARGE B‐CELL LYMPHOMA (DLBCL).
- Published in:
- Hematological Oncology, 2019, v. 37, p. 512, doi. 10.1002/hon.196_2631
- By:
- Publication type:
- Article
EG‐011 IS A NOVEL SMALL MOLECULE WITH IN VITRO AND IN VIVO ANTI‐TUMOR ACTIVITY AGAINST LYMPHOMA.
- Published in:
- Hematological Oncology, 2019, v. 37, p. 513, doi. 10.1002/hon.197_2631
- By:
- Publication type:
- Article
A MULTICENTER, OPEN LABEL, UNCONTROLLED, PHASE II TRIAL EVALUATING SAFETY AND EFFICACY OF VENETOCLAX, ATEZOLIZUMAB ANDOBINUTUZUMAB IN RICHTER TRANSFORMATION FROM CLL.
- Published in:
- Hematological Oncology, 2019, v. 37, p. 557, doi. 10.1002/hon.4_2632
- By:
- Publication type:
- Article
The progeny of a cosmic titan: a massive multi-component proto-supercluster in formation at z = 2.45 in VUDS.
- Published in:
- Astronomy & Astrophysics / Astronomie et Astrophysique, 2018, v. 619, p. N.PAG, doi. 10.1051/0004-6361/201833655
- By:
- Publication type:
- Article
Lyα-Lyman continuum connection in 3.5 ≤ z ≤ 4.3 star-forming galaxies from the VUDS survey.
- Published in:
- Astronomy & Astrophysics / Astronomie et Astrophysique, 2018, v. 614, p. N.PAG, doi. 10.1051/0004-6361/201732133
- By:
- Publication type:
- Article
The VIMOS Ultra Deep Survey: Luminosity and stellar mass dependence of galaxy clustering at z ∼3.
- Published in:
- Astronomy & Astrophysics / Astronomie et Astrophysique, 2018, v. 612, p. 1, doi. 10.1051/0004-6361/201730734
- By:
- Publication type:
- Article
ETS1 POSITIVELY REGULATES FAIM3 IN ACTIVATED B CELL-LIKE (ABC) DIFFUSE LARGE B CELL LYMPHOMA (DLBCL).
- Published in:
- Hematological Oncology, 2017, v. 35, p. 56, doi. 10.1002/hon.2437_42
- By:
- Publication type:
- Article
METABOLIC HETEROGENEITY OF BASELINE 18-FDG PET-CT SCAN PREDICTS OUTCOME IN PRIMARY MEDIASTINAL B-CELL LYMPHOMA.
- Published in:
- Hematological Oncology, 2017, v. 35, p. 60, doi. 10.1002/hon.2437_47
- By:
- Publication type:
- Article
Genotyping of Classical Hodgkin Lymphoma on the Liquid Biopsy.
- Published in:
- Hematological Oncology, 2017, v. 35, p. 64, doi. 10.1002/hon.2437_51
- By:
- Publication type:
- Article
THE RISK OF TRANSFORMATION OF FOLLICULAR LYMPHOMA 'TRANSFORMED' BY RITUXIMAB: THE ARISTOTLE STUDY PROMOTED BY THE EUROPEAN LYMPHOMA INSTITUTE.
- Published in:
- Hematological Oncology, 2017, v. 35, p. 115, doi. 10.1002/hon.2437_104
- By:
- Publication type:
- Article